Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-γc-/- double knockout mice

被引:47
|
作者
Fast, Loren D.
DiLeone, Gilbert
Cardarelli, Gene
Li, Junzhi
Goodrich, Raymond
机构
[1] Brown Univ, Rhode Isl Hosp, Dept Med, Div Hematol Oncol, Providence, RI 02903 USA
[2] Rhode Isl Hosp, Dept Radiat Oncol, Providence, RI 02903 USA
[3] Navigant Biotechnol, Lakewood, CO USA
关键词
D O I
10.1111/j.1537-2995.2006.00939.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Mirasol PRT (Navigant Biotechnologies) treatment utilizes exposure to light in the presence of riboflavin to introduce irreparable lesions to nucleic acids thereby inhibiting pathogen and WBC replication. The ability of Mirasol PRT-treated mononuclear cells (MNCs) to generate xenogeneic graft-versus-host disease (GVHD) responses was used to model transfusion-associated GVHD (TAGVHD). STUDY DESIGN AND METHODS: Pairs of human MNCs from five different individual donors that had or had not received Mirasol PRT treatment and contained 30 x 10(6) CD3+ cells were injected intraperitoneally into sublethally irradiated (350 cGy) Rag2(-/-)gamma c(-/-) double-knockout mice. Recipient mice were weighed and observed regularly and euthanized when they exhibited symptoms of GVHD or at termination of the experiment. Recipient lymphoid compartments were collected and phenotyped for the presence of human lymphoid cells. The presence of human cytokines and/or immunoglobulins in the recipient plasma was also used to detect the presence of human cells. RESULTS: Twelve of 14 mice injected with untreated cells developed xenogeneic GVHD, whereas 0 of 14 mice injected with Mirasol PRT-treated cells developed xenogeneic GVHD. End-stage xenogeneic GVHD in the recipients of untreated cells was characterized by the presence of splenic human cytolytic CD4+ and CD8+ cells, with high levels of interferon-gamma, interleukin-10, and xenoreactive antibodies in the plasma. CONCLUSION: Mirasol PRT treatment of the donor MNCs abolished xenogeneic GVHD responses, indicating that the use of Mirasol PRT treatment of blood products should prevent the development of TAGVHD.
引用
收藏
页码:1553 / 1560
页数:8
相关论文
共 30 条
  • [1] Mirasol® PRT treatment of human white blood cells prevents the development of xenogeneic graft-versus-host disease
    Fast, LD
    DiLeone, GR
    Li, J
    Goodrich, RP
    TRANSFUSION, 2005, 45 (03) : 28A - 29A
  • [2] Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-γc-/- immunodeficient mice
    Mutis, Tuna
    van Rijn, Rozemarijn S.
    Simonetti, Elles R.
    Aarts-Riemens, Tineke
    Emmelot, Maarten E.
    van Bloois, Louis
    Martens, Anton
    Verdonck, Leo F.
    Ebeling, Saskia B.
    CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5520 - 5525
  • [3] Induction of xenogeneic graft-versus-host disease through administration of HuPBMC to immune deficient RAG2-/-γc-/- mice:: A model for B cell-involvement in chronic graft-versus-host disease.
    Canninga-van Dijk, MC
    van Rijn, RS
    Simonetti, ER
    Hogenes, MC
    Smulders, S
    de Weger, RA
    Hagenbeek, A
    de Tweel, JGV
    Verdonck, LF
    Martens, ACM
    Ebeling, SB
    BLOOD, 2005, 106 (11) : 866A - 867A
  • [4] A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- γc-/- double-mutant mice
    van Rijn, RS
    Simonetti, ER
    Hagenbeek, A
    Hogenes, MCH
    de Weger, RA
    Canninga-van Dijk, MR
    Weijer, K
    Spits, H
    Storm, G
    van Bloois, L
    Rijkers, G
    Martens, ACM
    Ebeling, SB
    BLOOD, 2003, 102 (07) : 2522 - 2531
  • [5] A new in vivo model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/-γc-/- double mutant mice.
    van Rijn, RS
    Simonetti, ER
    Hogenes, MCH
    Storm, G
    Hagenbeek, A
    Spits, H
    Weijer, K
    Martens, ACM
    Ebeling, SB
    BLOOD, 2002, 100 (11) : 821A - 821A
  • [6] Contribution of Human T Cell Subpopulations to Xenogeneic Graft-Versus-Host Disease In RAG2-/-gc-/- Mice.
    Borsotti, Chiara
    Muller, Rouven
    Yamasaki, Masao
    Manz, Markus G.
    BLOOD, 2010, 116 (21) : 1053 - 1053
  • [7] Histological Assessment of the Sclerotic Graft-versus-Host Response in the Humanized RAG2-/-γc-/- Mouse Model
    Hogenes, Marieke C. H.
    van Dorp, Suzanne
    van Kuik, Joyce
    Monteiro, Filipa R. P.
    ter Hoeve, Natalie
    van Dijk, Marijke R.
    Martens, Anton C.
    de Weger, Roel A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (07) : 1023 - 1035
  • [8] MESENCHYMAL STROMAL CELLS CAN PREVENT GRAFT-VERSUS-HOST DISEASE IN A NOD/SCID γc- XENOGENEIC MOUSE MODEL
    Gregoire-Gauthier, Joelle
    Selleri, Silvia
    Fontaine, Francois
    Haddad, Elie
    PEDIATRIC TRANSPLANTATION, 2011, 15 : 128 - 128
  • [9] 2-Methoxyestradiol Treatment Prevents Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Effect in Mice
    Li, Dan
    Patenia, Rebecca
    Molldrem, Jeffrey
    Alousi, Amin M.
    Champlin, Richard E.
    Ma, Qing
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S405 - S406
  • [10] SPECIFIC DESTRUCTION OF HOST-REACTIVE MATURE T-CELLS OF DONOR ORIGIN PREVENTS GRAFT-VERSUS-HOST DISEASE IN CYCLOPHOSPHAMIDE-INDUCED TOLERANT MICE
    ETO, M
    MAYUMI, H
    TOMITA, Y
    YOSHIKAI, Y
    NISHIMURA, Y
    MAEDA, T
    ANDO, T
    NOMOTO, K
    JOURNAL OF IMMUNOLOGY, 1991, 146 (05): : 1402 - 1409